Clear-cell metastatic renal cell carcinoma: all 70 studies

Page 1 of 1. Open to participants first (31), then studies with results posted, then the rest; newest registration first within each.

• Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07828249Phase 1
• TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07776717Phase 2
• Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07748988Phase 1
• Imaging Study in Metastatic Clear Cell RCC.RecruitingNCT07671417Early Phase 1
• The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07645690Early Phase 1
• CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate RiskRecruitingNCT07615348Phase 2
• Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyNot yet recruitingNCT07578025Phase 2
• Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialNot yet recruitingNCT07576725Phase 2
• Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaRecruitingNCT07551349Phase 1/2
• VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07510334Phase 2
• Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical StudyEnrolling by invitationNCT07488572Phase 2
• Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingNCT07383441Phase 3
• Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell CarcinomaRecruitingNCT07300241Phase 1
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerRecruitingNCT07227415Phase 1/2
• A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingNCT07195682Phase 1
• Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerRecruitingNCT07128680Phase 1
• Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone MetastasesRecruitingNCT07043608Phase 2
• Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaRecruitingNCT07011719Phase 3
• Imaging of Solid Tumors Using 18F-TRXRecruitingNCT06942104Phase 1
• Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON TrialRecruitingNCT06866262Phase 1/2
• Radiopharmaceutical Treatment of Advanced Kidney CancerRecruitingNCT06783348Phase 2
• [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT06428708Early Phase 1
• CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney CancerRecruitingNCT06399419Phase 1
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic PlatformRecruitingNCT06349642
• 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT05879471Phase 2
• The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN TrialRecruitingNCT05753839Not applicable
• Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid TumoursNot yet recruitingNCT05698238Phase 1
• Pembrolizumab Plus Radiotherapy for Advanced Renal CancerRecruitingNCT05567588Phase 2
• Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyRecruitingNCT05361720Phase 2
• Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine TumorsRecruitingNCT05263050Phase 2
• Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialRecruitingNCT04510597Phase 3
• A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.CompletedNCT05745142Results posted
• Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing SurgeryTerminatedNCT04370509Phase 2Results posted
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)CompletedNCT03679767Phase 2Results posted
• Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT03334409Phase 2Results posted
• Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney CancerTerminatedNCT03260504Phase 1Results posted
• Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell CarcinomaTerminatedNCT02781506Phase 2Results posted
• MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell CarcinomaCompletedNCT02724020Phase 2Results posted
• High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal CancerCompletedNCT01896271Phase 2Results posted
• A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for NephrectomyCompletedNCT01693822Phase 2Results posted
• Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)CompletedNCT01472081Phase 1Results posted
• A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell CarcinomaTerminatedNCT01391130Phase 2Results posted
• RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyWithdrawnNCT07218692Phase 2
• Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)WithdrawnNCT07179770Phase 1
• Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in PatientsCompletedNCT06389682Phase 1/2
• PSMA Therapy and Immunotherapy in Kidney CancerWithdrawnNCT06361810Phase 1/2
• AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)Active, not recruitingNCT06245915Phase 1/2
• Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal CancerCompletedNCT06059014Phase 1/2
• Seleno-L Methionine (SLM)-Axitinib-PembrolizumabCompletedNCT05363631Phase 1/2
• CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerActive, not recruitingNCT05122546Phase 1
• Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerActive, not recruitingNCT05012371Phase 2
• Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerTerminatedNCT04904302Phase 2
• Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaActive, not recruitingNCT04696731Phase 1
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersActive, not recruitingNCT04388852Phase 1
• Combining Radiosurgery and Nivolumab in the Treatment of Brain MetastasesCompletedNCT02978404Phase 2
• A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerCompletedNCT02960906Phase 2
• Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell CarcinomaCompletedNCT02917772Phase 2
• Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)Status unknownNCT02880943Phase 1/2
• Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell CarcinomaCompletedNCT02848768
• Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF TherapyTerminatedNCT02570789Phase 4
• A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerTerminatedNCT02543645Phase 1
• Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers DiscoveryTerminatedNCT02535351Phase 3
• A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell CarcinomaTerminatedNCT02386111Phase 1
• IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC)CompletedNCT02228954
• Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With SunitinibCompletedNCT02019576Phase 2
• Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal CancerCompletedNCT02002312Phase 2
• Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With EverolimusCompletedNCT01715935Phase 2
• First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell CarcinomaCompletedNCT01521715Phase 4
• Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell CarcinomaCompletedNCT01510119Phase 1/2
• Study of Efficacy and Safety of Sunitinib Given on an Individualized ScheduleCompletedNCT01499121Phase 2

← Clear-cell metastatic renal cell carcinoma overview